[{"id":"d0527478-cd05-4416-b5a5-992a14d14ac7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03385486","created_at":"2021-05-11T12:52:51.133Z","updated_at":"2024-07-02T16:36:11.051Z","phase":"Phase 1","brief_title":"Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03385486","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/02/2019","start_date":" 06/02/2019","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-03"},{"id":"91376b42-a448-49fc-b024-9ff401ca6c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04640246","created_at":"2021-05-11T12:53:09.487Z","updated_at":"2024-07-02T16:36:17.708Z","phase":"Phase 1/2","brief_title":"Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies","source_id_and_acronym":"NCT04640246","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-02-02"}]